Antibodies against type I interferon: detection and association with severe clinical outcome in COVID‐19 patients

• DOI: 10.1002/cti2.1327
• Publication Date: 2021-08-17T17:02:28Z
• Authors: David Goncalves; Mehdi Mezidi; Paul Bastard; Magali Perret; Kahina Saker; Nicole Fabien; Rémi Pescarmona; Christine Lombard; Thierry Walzer; Jean‐Laurent Casa...; Alexandre Belot; Jean‐Christophe R...; Sophie Trouillet‐...
• Keywords: 2019-20 coronavirus outbreak; Interferon type I

Impairment of type I interferon (IFN-I) immunity has been reported in critically ill COVID-19 patients. This defect can be explained a subset patients by the presence circulating autoantibodies (auto-Abs) against IFN-I. We set out to improve detection and quantification IFN-I auto-Abs cohort patients, order better evaluate prevalence these Abs as pandemic progresses, how they correlate with clinical course disease. The concentration anti-IFN-α2 was determined serum 84 who were admitted ICU Hospices Civils de Lyon, France, using commercially available kit (Thermo Fisher, Catalog #BMS217). A total 21 (25%) had above cut-off (> 34 ng mL-1). Among them, 15 neutralising activity IFN-α2, that is (18%) In addition, we noticed an impairment response majority Abs. There no significant difference characteristics or outcome without auto-Abs. detected patients' sera throughout their stay. Finally, also found multiple subtypes including IFN-ω. 18% positive for auto-Abs, whereas all mild negative, confirming antibodies associated higher risk developing critical form.